EVLO — Evelo Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Evelo Biosciences falls as co to discontinue eczema drug development
Brief: Evelo Biosciences Provides Clinical Updates
Brief: Evelo Biosciences Inc - On March 16, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Evelo Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Evelo Biosciences Announces Fourth Quarter And Full Year 2022 Financial Results And Business Highlights
Evelo Biosciences Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Evelo Biosciences Inc Says Following David Epstein's Resignation, Size Of Co's Board Was Reduced From Ten To Nine Directors
Evelo Biosciences rises on plan to reduce workforce
Brief: Evelo Biosciences Approved A Plan To Reduce Its Workforce By 48 Employees
U.S. RESEARCH ROUNDUP-Evelo Biosciences, Homestreet, O-I Glass
Evelo Biosciences hits record low after eczema drug fails study
U.S. STOCKS ON THE MOVE-Tesla, Peloton, Thermo Fisher Scientific
Evelo Biosciences to cut jobs, skin disease drug trial disappoints (updated)
Evelo Biosciences slumps on eczema drug failing study, job cuts
Evelo Biosciences to cut jobs, skin disease drug trial disappoints
Brief: Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
Brief: Evelo Biosciences Announces $45 Million Loan Agreement With Horizon Technology Finance Corporation To Refinance Existing Debt
Evelo Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Evelo Biosciences Reports Third Quarter 2022 Financial Results, Business Highlights